Skip to content

Atellica IM FT3 10995584Recalls & reported problems

Siemens Healthcare Diagnostics Inc. · Free T3 (FT3) Atellica IM - RGT 300T · Class 2

Data updated Oct 18, 2026 from official FDA records · Editorial policy

Adverse event reports
1
Deaths reported
0
Injuries reported
0
Recalls naming it
0

Summary

The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 00630414599083), received between Aug 16, 2023 and Aug 16, 2023 — classified as 1 malfunction.

The most frequently reported specific device problem is “Low Test Results” (1 report).

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.

Most reported problems

Device problems

  • Low Test Results1

Patient problems

  • No Clinical Signs, Symptoms or Conditions1

Recent adverse event reports

The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.

  • MalfunctionAug 16, 2023Low Test Results; Low Test Results

    THE CUSTOMER DOES NOT ROUTINELY RUN THE FREE TRIIODOTHYRONINE (FT3) TEST ON THE ATELLICA IM, HOWEVER, THE CUSTOMER OBSERVED RESULTS FROM TWO PATIENT SAMPLES WERE DEPRESSED COMPARED TO TESTING ON THE ADVIA CENTAUR FT3 AND AN ALTERNATE METHOD FT3 ASSAY. THE ATELLICA IM FT3 RESULTS WERE NOT REPORTED TO THE PHYSICIAN. THERE ARE NO KNOWN REPORTS OF PATIENT INTERVENTION OR ADVERSE HEALTH CONSEQUENCES DUE TO THE DISCORDANT DEPRESSED FT3 PATIENT RESULTS.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 17556943 ↗

Other RADIOIMMUNOASSAY, TOTAL TRIIODOTHYRONINE devices

All RADIOIMMUNOASSAY, TOTAL TRIIODOTHYRONINE devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page